Semax: ACTH(4-7)PGP Heptapeptide Research Profile

What Is Semax?

Semax is a synthetic heptapeptide with the sequence Methionine-Glutamic acid-Histidine-Phenylalanine-Proline-Glycine-Proline (Met-Glu-His-Phe-Pro-Gly-Pro, or MEHFPGP). Public chemistry databases list the free-base form as C₃₇H₅₁N₉O₁₀S, with a molar mass of about 813.9 g/mol.^[1] It is a designed molecule with two functional halves: the N-terminal ACTH(4-7) fragment (Met-Glu-His-Phe), which coincides with a segment of α-melanocyte-stimulating hormone, and a C-terminal Pro-Gly-Pro tripeptide added specifically to slow enzymatic degradation and extend the peptide's half-life.

Semax was synthesised at the Institute of Molecular Genetics of the Russian Academy of Sciences under the academicians I. P. Ashmarin and N. F. Myasoedov. In Russia it is a registered neuroprotective drug used for ischemic stroke, transient ischemic attack, and cognitive/nootropic indications, and it appears on the Russian list of vital and essential medicines. Outside Russia and a few neighbouring markets it has no regulatory approval.^[1]

For a research reader, the practical takeaway is that Semax is best understood as a neuroprotection / nootropic tool compound with an unusually detailed rodent mechanism story and a real — but methodologically limited — clinical footprint. The literature gives clear preclinical signals to study; outside Russia it does not give an approved clinical product.

Where Semax Sits in the Melanocortin / ACTH Story

ACTH and α-MSH share an N-terminal sequence, and short melanocortin fragments have long been studied for effects on learning, attention, and neuroprotection that are separable from the hormone's classic endocrine role. Semax's N-terminal Met-Glu-His-Phe is exactly the ACTH(4-7) fragment that overlaps α-MSH, which is why the peptide is described as a melanocortin-derived neuropeptide rather than a novel scaffold.^[2]

The engineering trick that makes Semax usable is the C-terminal Pro-Gly-Pro (PGP). Native ACTH fragments are degraded quickly by peptidases; appending the biogenic PGP tripeptide substantially increases metabolic stability, which is what allows intranasal Semax to reach the brain and act over a useful window.^[2]

It is worth being precise about what that does and does not mean. The melanocortin lineage explains why Semax was expected to have central effects, and the PGP stabilisation explains why it is practical to administer. Neither fact, on its own, establishes clinical efficacy — that is a separate, trial-level question.

Mechanism: BDNF/NGF Induction and Anti-Inflammatory Neuroprotection

Semax has one of the more thoroughly mapped rodent mechanisms among the research peptides, largely because Russian molecular-genetics groups have profiled it at the transcriptome and protein level in a standard stroke model. Two findings anchor the modern narrative:

• Neurotrophin induction. Across cerebral-ischemia models, Semax enhances the transcription of neurotrophins — especially BDNF and NGF — and their receptors, which is the mechanistic basis for its "neurotrophic / nootropic" description.^[3]
• Anti-inflammatory transcriptome shift. Genome-wide RNA-Seq in the rat transient middle cerebral artery occlusion (tMCAO) model identified hundreds of differentially expressed genes under Semax; the peptide suppressed proinflammatory gene induction and activated neurotransmitter-related genes, helping normalise ischemia-disrupted expression patterns.^[3]

A complementary protein-level study confirmed the direction of effect: 24 hours after tMCAO, Semax-treated brains showed upregulated active CREB (a recovery/neuroprotection signal) alongside downregulated MMP-9, c-Fos, and active JNK (inflammation and cell-death signals) in the ischemic focus and adjacent cortex.^[2] Reviews also emphasise Semax's low toxicity and the absence of dependence, withdrawal, or cardiovascular liabilities in the reported profile.^[1]

What this gives a research reader is a coherent, multi-level mechanistic picture — neurotrophin induction plus an anti-inflammatory, pro-recovery transcriptional shift — rather than a single-receptor claim. That is a genuine strength relative to many research peptides; the weakness is on the clinical side.

The Clinical Record: Russian Stroke Trials

Semax's human evidence comes almost entirely from Russian ischemic-stroke research led by the Gusev group.

1. Early clinical / electrophysiological work (Gusev et al., 1997)

An early study compared 30 patients with acute hemispheric ischemic stroke receiving Semax (12–18 mg/day for 5–10 days depending on severity) against 80 patients with comparable strokes on conventional therapy, reporting clinical and electrophysiological signals in favour of the Semax arm. As an early, small, non-blinded comparison, it is best read as hypothesis-generating.^[4]

2. Best-powered study (Gusev, Martynov et al., 2018)

The most recently published and best-powered Semax stroke study on PubMed enrolled 110 post-stroke patients (43 men, 67 women; mean age ~58) receiving intranasal Semax at 6,000 mcg/day in two 10-day courses separated by a 20-day interval. Over a ~5-month observation window, the study reported elevated plasma BDNF and improved Barthel index and MRC motor-scale scores in both early- and late-rehabilitation subgroups versus comparator subgroups.^[4]

The limitations are as important as the result. The 2018 study was neither randomized nor placebo-controlled, and the published abstract did not report numerical effect sizes, confidence intervals, or p-values. Much of the broader Semax literature is Russian-language and has not been independently replicated in Western randomized trials. The honest posture is that the mechanism is strong and the clinical signal is suggestive but low-certainty.

Semax vs Epitalon vs BPC-157 — Different Lanes

Researchers often group Semax with other short "research heritage" peptides. The honest answer is that the commonly compared compounds belong to different families and were investigated in different model systems. The table below summarises that, without claiming clinical interchangeability.

None of these molecules is an FDA-approved therapeutic, and none has an independently replicated late-stage human-trial program of the kind seen with incretin agents. For research framing, the cleanest position is to keep Semax in the neuroprotection / nootropic lane, with Epitalon in the pineal-geroprotection lane and BPC-157 in the recovery/repair-signalling lane. They are not substitutes for each other in a research-design sense.

What the Semax Literature Does Not Yet Give You

Cautious reading of Semax requires acknowledging four real gaps:

• No Western randomized trial. The human evidence is Russian, largely non-randomized and not placebo-controlled, and unreplicated by independent Western groups. Anyone framing Semax as a proven stroke or cognition therapeutic outside Russia is going beyond the published record.^[4]
• Reporting gaps in the key trial. The best-powered 2018 study did not publish effect sizes, confidence intervals, or p-values in its abstract, which limits how much weight the positive result can bear.^[4]
• Mechanism strong, translation unproven. A detailed rodent transcriptome/protein mechanism does not guarantee a clinically meaningful effect in humans; many neuroprotectants with clean animal data have failed in rigorous stroke trials.^[2][3]
• Dose translation is unsupported here. This article makes no attempt to translate published human or animal doses into a protocol. Anyone offering specific "Semax protocols" as medical guidance is going outside the scope of this research review.

These gaps are not arguments against studying Semax. They are arguments against overselling it.

Where Semax Fits in a Modern RUO Research Catalog

For research use, Semax belongs in the category of neuroactive / nootropic peptide research tools — typically supplied as a lyophilized research vial with cold-chain handling, reconstituted with bacteriostatic water for in-vitro work, and published against a >99% HPLC line standard. That format is consistent with how investigators have used the peptide in cell-culture and animal-model work in the published literature.

It is not framed for human use, not framed for veterinary use, and not framed as a treatment. The wider compound comparison sits in the research library, and published Janoshik reports for the Retatrutide range sit in the COA library.

For researchers reading this page as a starting point, the most useful adjacent references on this site are the peptide primer, the bacteriostatic water guide, the stability and storage guide, and the peptide legality brief. Researchers comparing Semax to other neuro/geroprotective peptides may also want the Epitalon research review.

FDA PCAC votes July 23–24, 2026: six peptides recommended

The FDA Pharmacy Compounding Advisory Committee concluded its July 23–24, 2026 meeting by voting to recommend six of the seven candidate peptides for the 503A Bulks List, in free base and acetate forms where applicable: BPC-157 (8–6, one abstention; evaluated use: ulcerative colitis), KPV (8–6, one abstention; wound healing and inflammatory conditions), TB-500 (8–6, one abstention; wound healing), MOTS-c (7–5, two abstentions; obesity and osteoporosis), Epitalon (insomnia), and Semax (8–5, one abstention; cerebral ischemia, migraine, trigeminal neuralgia). Emideltide (DSIP) was the only candidate not recommended (6–7, one abstention).

The recommendations are advisory, and FDA’s own scientific review staff opposed inclusion of all seven peptides, so the agency may still depart from the committee. Formal notice-and-comment rulemaking — which commonly takes a year or more — must conclude before any 503A list change takes effect. No compound gained an approved indication, and the votes do not change the research-only status of any research-grade peptide. Sources: FDA meeting page and materials; McDermott Will & Schulte meeting analysis. Full tallies and rulemaking outlook: PCAC explainer.